title: [Ocular cicatricial pemphigoid - state of the art in clinic and therapy for a problematic disease].
abstract: The ocular cicatricial pemphigoid (OCP) belongs to a family of chronically progressive autoimmune disorders, predominantly affecting mucous membranes (mucous membrane pemphigoids). It is an immunopathologically heterogeneous group of disorders with variable phenotypes that share the unique feature of a subepidermal blistering, through disruption of the adhesion between epidermis and dermis. A key feature is the chronically active inflammation with consecutive fibrosis, leading to a partial or complete loss of function of the affected organ. The ocular disease as a chronic cicatrising conjunctivitis is a common manifestation of the mucous membrane pemphigoid. The identification of the subtle pathology and the prompt initiation of an appropriate therapy are of pivotal importance. One purpose is to prevent further vision loss due to extensive corneal scarring and life-threatening systemic complications, such as the formation of oesophageal or tracheal strictures. So far there are no prospective, randomised studies, regarding the therapy guidelines with an evidence level more than III. The autoimmune nature of the disease implies that systemic immunosuppression is the only effective treatment option, most notably in extended stages. The aim of our study is to give a guideline for a stage adjusted therapy with conventional immunosuppressants and to give a perspective for alternative therapies, especially for recalcitrant disease.
authors: Universitäts-Augenklinik, Charité Campus Virchow-Klinik, Berlin.
authors: A
authors: A
authors: Rübsam
authors: J P
authors: JP
authors: Klein
authors: U
authors: U
authors: Pleyer
mesh_terms: D003937:Diagnosis, Differential; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D009885:Ophthalmology / Q000592:standards*; D010390:Pemphigoid, Benign Mucous Membrane / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D014786:Vision Disorders / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control*
chemical_list: D007166:Immunosuppressive Agents